Niaprazine

• CAT Number: I033247
• CAS Number: 27367-90-4
• Molecular Formula: C20H25FN4O
• Molecular Weight: 356.4454
• Purity: 98%
• Synonyms: Niaprazine
• Target: Neuronal Signaling
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: N-(3-(4-(4-Fluorophenyl)-1-piperazinyl)-1-methylpropyl)-3-pyridinecarboxamide
• InChI: InChI=1S/C20H25FN4O/c1-16(23-20(26)17-3-2-9-22-15-17)8-10-24-11-13-25(14-12-24)19-6-4-18(21)5-7-19/h2-7,9,15-16H,8,10-14H2,1H3,(H,23,26)
• InChIKey: RSKQGBFMNPDPLR-UHFFFAOYSA-N
• SMILES: O=C(C1=CC=CN=C1)NC(C)CCN2CCN(C3=CC=C(F)C=C3)CC2

Niaprazine is a selective brain catecholamine depletor.

Reference

1: Keane PE, Strolin Benedetti M, Dow J. The effect of niaprazine on the turnover of 5-hydroxytryptamine in the rat brain. Neuropharmacology. 1982 Feb;21(2):163-9. doi: 10.1016/0028-3908(82)90157-5. PMID: 6460945.
2: Rossi PG, Posar A, Parmeggiani A, Pipitone E, D’Agata M. Niaprazine in the treatment of autistic disorder. J Child Neurol. 1999 Aug;14(8):547-50. doi: 10.1177/088307389901400814. PMID: 10456769.
3: Pisciotta L, Gherzi M, Stagnaro M, Calevo MG, Giannotta M, Vavassori MR, Veneselli E; I.B.AHC Consortium, De Grandis E. Alternating Hemiplegia of Childhood: Pharmacological treatment of 30 Italian patients. Brain Dev. 2017 Jun;39(6):521-528. doi: 10.1016/j.braindev.2017.02.001. Epub 2017 Feb 27. PMID: 28249736.
4: Scherman D, Hamon M, Gozlan H, Henry JP, Lesage A, Masson M, Rumigny JF. Molecular pharmacology of niaprazine. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(6):989-1001. doi: 10.1016/0278-5846(88)90093-0. PMID: 2853885.
5: Niederhofer H. Niaprazine may improve some symptoms of attention-deficit hyperactivity disorder. Minerva Pediatr. 2010 Apr;62(2):231-2. PMID: 20440244.
6: Franzoni E, Masoni P, Mambelli M, Marzano P, Donati C. La niaprazina nei disturbi del comportamento del bambino. Confronto in doppio cieco contro placebo [Niaprazine in behavior disorders in children. Double-blind comparison with placebo]. Pediatr Med Chir. 1987 Mar-Apr;9(2):185-7. Italian. PMID: 2958783.
7: Keane PE, Benedetti MS. Niaprazine, a selective brain catecholamine depletor. Neuropharmacology. 1979 Jul;18(7):595-600. doi: 10.1016/0028-3908(79)90110-2. PMID: 158713.
8: Pozzi M, Conti V, Locatelli F, Galbiati S, Radice S, Clementi E, Strazzer S. Paroxysmal Sympathetic Hyperactivity in Pediatric Rehabilitation: Pathological Features and Scheduled Pharmacological Therapies. J Head Trauma Rehabil. 2017 Mar/Apr;32(2):117-124. doi: 10.1097/HTR.0000000000000255. PMID: 27603764.
9: Montanari G, Schiaulini P, Covre A, Steffan A, Furlanut M. Niaprazine vs chlordesmethyldiazepam in sleep disturbances in pediatric outpatients. Pharmacol Res. 1992 Feb-Mar;25 Suppl 1:83-4. doi: 10.1016/1043-6618(92)90551-l. PMID: 1354861.
10: Ottaviano S, Giannotti F, Cortesi F. The effect of niaprazine on some common sleep disorders in children. A double-blind clinical trial by means of continuous home-videorecorded sleep. Childs Nerv Syst. 1991 Oct;7(6):332-5. doi: 10.1007/BF00304832. PMID: 1837245.
11: Bodiou C, Bavoux F. Niaprazine et effets indésirables en pédiatrie. Bilan coopératif des centres français de pharmacovigilance [Niaprazine and side effects in pediatrics. Cooperative evaluation of French centers of pharmacovigilance]. Therapie. 1988 Jun-Jul;43(4):307-11. French. PMID: 2903572.
12: Sarda H, Benkhelifa S, Housset C, Le Loc’h H. Malaise après niaprazine (Nopron) [Syncope after niaprazine (Nopron)]. Arch Pediatr. 1996 Jan;3(1):90. French. doi: 10.1016/s0929-693x(96)80020-0. PMID: 8745837.
13: Duchene-Marullaz P, Rispat G, Perriere JP, Hache J, Labrid C. De quelques propriétés pharmacodynamiques de la niaprazine, nouvel antihistaminique [Some pharmacodynamical properties of niaprazine, a new antihistaminic agent]. Therapie. 1971 Nov-Dec;26(6):1203-9. French. PMID: 4401719.
14: Auduy B. Défaillance cardio-respiratoire aiguë après absorption de niaprazine [Acute cardio-respiratory failure after niaprazine absorption]. Arch Fr Pediatr. 1988 Jun-Jul;45(6):439. French. PMID: 2905885.
15: Veneselli E, Biancheri R. Alternating hemiplegia of childhood: treatment of attacks with chloral hydrate and niaprazine. Eur J Pediatr. 1997 Feb;156(2):157-8. PMID: 9039526.
16: Younus M, Labellarte MJ. Insomnia in children: when are hypnotics indicated? Paediatr Drugs. 2002;4(6):391-403. doi: 10.2165/00128072-200204060-00006. PMID: 12038875.
17: Lee W, Day TJ, Williams DR. Clinical, laboratory and electrophysiological features of Morvan’s fibrillary chorea. J Clin Neurosci. 2013 Sep;20(9):1246-9. doi: 10.1016/j.jocn.2012.10.029. Epub 2013 May 24. PMID: 23712055.
18: Dostert P, Strolin Benedetti M, Rovei V, Smith RL. Can a 1,2-oxygen shift of a nicotinamide N-oxide derivative occur in vivo? Xenobiotica. 1985 Oct;15(10):799-803. doi: 10.3109/00498258509045031. PMID: 2933883.
19: Mancini J, Thirion X, Masut A, Saillard C, Pradel V, Romain F, Pastor MJ, Coudert C, Micallef J. Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. Pharmacoepidemiol Drug Saf. 2006 Jul;15(7):494-503. doi: 10.1002/pds.1258. PMID: 16700077.
20: De Zen L, Del Rizzo I, Robazza M, Barbieri F, Campagna M, Vaccher S, Barbi E, Dall’Amico R. Home Use of Intranasal Dexmedetomidine in a Child With An Intractable Sleep Disorder. J Pediatr Pharmacol Ther. 2020;25(4):332-335. doi: 10.5863/1551-6776-25.4.332. PMID: 32461748; PMCID: PMC7243900.